Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 3/3/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Daniel J. Drucker

Wrong Dr. Daniel J. Drucker?

Senior Investigator

Local Address: Toronto, Ontario, Canada
Mount Sinai Hospital
1 Gustave Levy Place Box 1211
New York , New York 10029
United States

Company Description: Mount Sinai Hospital is recognized nationally and internationally for its excellence in the provision of compassionate patient care, teaching and research. Its key...   more

Employment History

Board Memberships and Affiliations

  • Director
    Best Diabetes Centre
  • Director
    U of T's Banting


  • M.D.
  • M.D. degree
    University of Toronto
169 Total References
Web References
Dr. Daniel Drucker, an ..., 3 Mar 2015 [cached]
Dr. Daniel Drucker, an endocrinologist and senior scientist at Mount Sinai Hospital in Toronto, is shown in a handout photo. Researchers are probing a link between bariatric surgery and higher colon cancer risk. THE CANADIAN PRESS/ HO-Mount Sinai Hospital - Dr. Daniel Drucker, an endocrinologist and senior scientist at Mount Sinai Hospital in Toronto, is shown in a handout photo. Researchers are probing a link between bariatric surgery and higher colon cancer risk. THE CANADIAN PRESS/ HO-Mount Sinai Hospital
And that appears to stimulate overproduction of a gut hormone that may spur the growth of polyps in the colon that have a propensity to become malignant, suggests Dr. Daniel Drucker, an endocrinologist at Mount Sinai Hospital in Toronto.
In studies in laboratory mice, a research team led by Drucker found the digestive hormone GLP-1 was "a pretty potent growth factor" for the intestine in the animals, as well as a catalyst for intestinal tumours in other lab mice specially bred to study colorectal cancer.
"If we gave the mice more GLP-1, they got more tumours," said Drucker, a senior scientist at the hospital's Lunenfeld-Tanenbaum Research Institute.
While Drucker is quick to point out that mice aren't humans, he said the animal studies go a long way in providing a biological explanation.
"So if you say under what conditions might a human find themselves with increased levels of GLP-1 and the risk for intestinal tumour formation, probably the best delineated situation is the condition of bariatric surgery," he said, explaining that patients have elevated levels of GLP-1, other digestive hormones and bile acids, which are all known to stimulate intestinal growth.
Calling bariatric surgery the best available treatment for obesity and Type 2 diabetes, Drucker said eligible patients shouldn't shy away from the operation but should ensure they have regular screening for colon cancer afterward.
"We're very conservative. We don't make clinical recommendations based on findings in mice," he stressed. "But we would say that given the already available data that patients with bariatric surgery might have an increased risk of colon cancer and our new findings providing an explanation for why that might happen - have your colonoscopies."
That's also the advice for those taking a class of drugs used for diabetes control that work by activating the GLP-1 receptor to increase insulin and decrease blood glucose.
"It's important to state that GLP-1 doesn't by itself ... cause intestinal tumours," said Drucker. "But what we believe is that if you already have a propensity to form a tumour - so if you had an intestinal polyp, which is very common - then we believe that the growth of that polyp would be increased if the levels of GLP-1 were elevated."
While the research, published Tuesday in the journal Cell Metabolism, needs to be replicated by other researchers and confirmed in humans, he said patients should discuss the potential link between increased GLP-1 and colon cancer with their doctors.
Dr. Daniel Drucker received the ..., 21 Jan 2015 [cached]
Dr. Daniel Drucker received the world's most valuable award for diabetes research, the 2014 Manpei Suzuki International Prize. Dr. Drucker, Senior Investigator at Mount Sinai Hospital's Lunenfeld-Tanenbaum Research Institute, was recognized for his research in the area of gut hormones and how they control glucose and body weight, which have led to the development of two new classes of therapies for the treatment of type 2 diabetes. (Full story here.)
Arisaph Pharmaceuticals : About : Scientific Advisory Board, 14 Jan 2015 [cached]
Daniel Drucker
Daniel J. Drucker, M.D., FRCPC Professor of Medicine, University of Toronto Director, Banting and Best Diabetes Centre, University of Toronto
Dr. Daniel J. Drucker is currently a Professor of Medicine, a member of the Endocrinology Division at the University of Toronto and Director of the Banting and Best Diabetes Centre at the University of Toronto. He is a foremost expert on the subject of enteric hormones. He received training in Internal Medicine and Endocrinology from Johns Hopkins Hospital in Baltimore and Toronto General Hospital, University of Toronto. Following completion of a research fellowship in Molecular Endocrinology at Massachusetts General Hospital, he established his own laboratory research program in 1987 in Toronto. His laboratory studies the synthesis, secretion, and mechanism of action of glucagon-like peptides. Specific areas of interest include how glucagon, GLP-1, GLP-2, and the enzyme DPP IV (dipeptidyl peptidase IV) regulate metabolic pathways that control food intake, nutrient absorption and disposal, and intestinal mucosal integrity. Dr. Drucker is an Editor of the journal Endocrinology, and the recipient of Outstanding Investigator Awards from the Canadian Diabetes Association, the Endocrine Society, and the Canadian Society for Clinical Investigation. He also has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. Dr. Drucker received his M.D. degree from the University of Toronto in 1980 and received his FRCPC in Internal Medicine from the Royal College of Physicians and Surgeons of Canada in 1984.
UHN: News, 7 Aug 2007 [cached]
"The commitment and resources deployed under this new partnership will significantly enhance our ability to achieve a global impact in research, education and clinical care of diabetes," said Dr. Daniel Drucker, Director of the BBDC.
Improving the health of Canadians with diabetes-- Dr. Dan Drucker recognized for exceptional contributions to diabetes research and patient care in Canada | Lunenfeld-Tanenbaum, 23 Jan 2012 [cached]
/ News / Improving the health of Canadians with diabetes-- Dr. Dan Drucker recognized for exceptional contributions to diabetes research and patient care in Canada (January 23, 2012-Toronto, ON) Dr. Daniel Drucker, Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Professor of Medicine and Director of the Banting and Best Diabetes Centre at the University of Toronto, has received a 2011 CIHR/CMAJ Top Achievements in Health Research Award, in recognition of his internationally renowned achievements in diabetes patient care and research. Dr. Drucker was one of six recipients of the award, included among exceptional researchers in Canada whose achievements changed the course of health care delivery in their field of work.
For the third year, a peer-review panel of Canadian and international experts selected exceptional individuals including Dr. Drucker, based on the considerable health impact of their work to benefit Canadians and others worldwide. Among the six outstanding achievements selected, Dr. Drucker was one of only two who received special mentions for their highest-ranking successes. "I am very pleased that the hard work and accomplishments of our research team over two decades have led to a greater understanding of the biology of gut hormones, and in turn, the development of new drugs for the treatment of diabetes," said Dr. Drucker. New therapies are greatly improving blood sugar control for people with diabetes-an illness that impacts thousands of Canadians. The two most recently approved drug classes for the treatment of type 2 diabetes, DPP-4 inhibitors and GLP-1R agonists (both widely used in Canada and helping to improve glucose control and quality of life), are based substantially on Dr. Drucker's research. He is now investigating the cardiovascular effects of these drugs, in parallel with seven major clinical cardiovascular outcome studies that are underway to rigorously assess the safety of these new drugs in patients with diabetes and heart disease. Dr. Drucker also contributed to the testing of a new once-weekly treatment for type 2 diabetes that may complement the more common twice-daily injection of exenatide, an advance that has significantly improved the quality of life for people with diabetes. A clinician-scientist at Mount Sinai since 2007, Dr. Drucker's leadership and achievements in diabetes research at the hospital have received both national and international recognition.
This reflects the remarkable impact Dr. Drucker has had on patients suffering from diabetes." Later this year, Dr. Drucker will become the first and only Canadian to receive the Claude Bernard Lecture/Award of the European Association for the Study of Diabetes (EASD), which is thehighest scientific achievement award of the EASD. He holds the Canada Research Chair in Regulatory Peptides; received the Prix Galien Canada Research Award in 2008 for his substantial contribution to the diagnosis, prevention or treatment of diseases; and the 2009 Clinical Investigator Award from The Endocrine Society. The incidence of type 2 diabetes has reached epidemic proportions worldwide and is a leading cause of heart disease, stroke, blindness, kidney failure and limb amputation. Several studies have shown that lifestyle changes and appropriate pharmacologic therapy can significantly reduce the development of type 2 diabetes in people at risk of the disease. Dr. Drucker's significant research discoveries mean improved health for millions of patients with type 2 diabetes worldwide. His key findings led to the development of several new classes of therapies for these patients. The new therapies reduced the need for self-monitoring of blood glucose levels and lowered the risk of hypoglycemia and weight gain. Currently, Dr. Drucker's lab at the Lunenfeld focuses on understanding the biology of glucagon-like peptides.
Other People with the name "Drucker":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.